Aarti Drugs Ltd.
NSE: AARTIDRUGS | BSE: 524348
₹383.45
₹1.80
(0.47%)
As on 21-May-2026 10:24IST
Market cap
₹3,482 Cr
Revenue (TTM)
₹2,565 Cr
P/E Ratio
17.9
P/B Ratio
2.2
Div. Yield
0.5 %
Quality Score
2/10
Growth Score
5/10
Valuation Score
5/10
Momentum Score
4/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹195 Cr
-
ROE
12.7 %
-
ROCE
13.1 %
-
Industry P/E
37.35
-
EV/EBITDA
13
-
Debt to Equity
0.2
-
Book Value
₹169.7
-
EPS
₹21.4
-
Face value
10
-
Shares outstanding
91,270,000
10 Years Aggregate
CFO
₹1,733.84 Cr
EBITDA
₹2,742.09 Cr
Net Profit
₹1,455.42 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aarti Drugs
| -6.9 | 5.0 | 3.0 | -18.2 | -5.8 | -12.7 | 12.3 |
|
BSE Healthcare
| 10.1 | 10.3 | 11.0 | 13.3 | 28.0 | 14.4 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aarti Drugs
| -9.6 | -7.1 | 6.3 | -15.6 | -25.9 | 376.5 | 0.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aarti Drugs
|
383.5 | 3,482.0 | 2,565.3 | 194.9 | 9.4 | 12.9 | 17.9 | 2.2 |
| 1,069.5 | 13,003.0 | 2,551.8 | 564.5 | 28.3 | 18.4 | 23 | 3.9 | |
| 1,722.7 | 32,846.4 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.5 | 6.6 | |
| 210.0 | 1,950.4 | 1,843.5 | -98.7 | 0.8 | -9.6 | -- | 2.1 | |
| 118.0 | 3,508.8 | 2,319.1 | 137.6 | 8.1 | 8.2 | 25.5 | 2.0 | |
| 16,634.0 | 21,331.6 | 2,023.0 | 364.0 | 23.9 | 20.8 | 58.6 | 11.4 | |
| 2,300.2 | 3,808.9 | 707.5 | 115.2 | 17.8 | 19.4 | 33.1 | -- | |
| 1,113.0 | 4,987.4 | 649.5 | 121.6 | 23.7 | 13.2 | 43.2 | 5.3 | |
| 568.3 | 2,768.8 | 1,369.0 | -7.4 | 6.4 | -0.1 | -- | 2.2 | |
| 272.0 | 7,090.1 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 12.0 |
Shareholding Pattern
View DetailsNews & Analysis
All News
2 min read•By Vikas Vardhan
About Aarti Drugs
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac,... celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India. Read more
-
Incorporated
1984
-
Chairman
Prakash M Patil
-
Managing Director
Rashesh C Gogri
-
Group
Aarti
-
Headquarters
Thane, Maharashtra
-
Website
Looking for more details about Aarti Drugs Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Aarti Drugs
What is the current share price of Aarti Drugs Ltd Today?
The share price of Aarti Drugs Ltd is ₹383.45 (NSE) and ₹383.90 (BSE) as of 21-May-2026 10:24 IST. Aarti Drugs Ltd has given a return of -5.85% in the last 3 years.
What is the current PB & PE ratio of Aarti Drugs Ltd?
The P/E ratio of Aarti Drugs Ltd is 17.86 times as on 20-May-2026, a 52 discount to its peers’ median range of 37.35 times.
The P/B ratio of Aarti Drugs Ltd is 2.25 times as on 20-May-2026, a 5 discount to its peers’ median range of 2.36 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.44
|
2.27
|
|
2024
|
23.27
|
3.11
|
|
2023
|
18.81
|
2.62
|
|
2022
|
19.37
|
3.83
|
|
2021
|
23.09
|
7.09
|
What is the 52 Week High and Low of Aarti Drugs Ltd?
The 52-week high and low of Aarti Drugs Ltd are Rs 564.05 and Rs 318.95 as of 21-May-2026.
What is the market cap of Aarti Drugs Ltd?
Aarti Drugs Ltd has a market capitalisation of ₹ 3,482 Cr as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aarti Drugs Ltd?
Before investing in Aarti Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.